Licensing Opportunity: Stabilized Norovirus Vaccine-like Particles (VLPs): A Next-Generation Vaccine Approach
National Institute of Allergy and Infectious Diseases sent this bulletin at 04/28/2025 12:51 PM EDT
Stabilized Norovirus Vaccine-like Particles (VLPs): A Next-Generation Vaccine Approach
Image Description: Creative layout featuring 3D renderings of norovirus virus-like particles (VLPs). Credit: NIAID
Recent estimates from the Centers for Disease Control (2020) indicate that roughly half of all foodborne disease outbreaks in the U.S. are caused by noroviruses.
Researchers at the National Institute of Allergy and Infectious Diseases (NIAID) have engineered enhanced virus-like particles (VLPs) with the potential for a more effective and robust response against norovirus infection. These VLPs are designed to remain intact even when faced with the body's immune responses, which may be particularly helpful in individuals with more robust immune systems who have shown limited responses to traditional vaccines. Additionally, these modified VLPs may be more resistant to degradation, making them a more reliable and durable solution in for large-scale immunization efforts.
To learn more about this collaboration opportunity, visit https://www.techtransfer.nih.gov/tech/tab-4517 or contact Brian Bailey at brian.bailey@nih.gov and reference E-178-2019.
#Norovirus #NIAID #Vaccine #Virus #NIAIDTechTransfer
Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. Your subscription may be removed if you do not open our emails for a six-month period.
This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).
